- Design
- Target trial emulation, new-user active-comparator cohort
- Population
- 28,547 adults with type 2 diabetes starting GLP-1RA or DPP-4i, Stockholm
- Primary outcome
- Five-year composite kidney outcome
- Effect
- Overall HR 0.84 (0.72–0.97); highest-risk quarter absolute reduction −2.76% (HR 0.70)
This study emulated a target trial using Stockholm health records from 2008 to 2021, comparing 11,772 people with type 2 diabetes starting a GLP-1 receptor agonist with 16,775 starting a DPP-4 inhibitor, and modelled who gained most.
Overall, GLP-1 receptor agonists were associated with a lower five-year risk of kidney outcomes (HR 0.84), though the absolute difference was small (−0.72%). In the highest quarter of predicted kidney failure risk, the absolute reduction was 2.76% (HR 0.70); in the lowest quarter there was no benefit. Lower eGFR, faster prior eGFR decline, higher albuminuria and higher HbA1c predicted the greatest benefit.
This is observational, but it matches the logic of targeting kidney-protective drugs where absolute risk is highest. It also suggests the kidney failure risk equation, already used in nephrology clinics, can help prioritise who gets a GLP-1 drug when supply or cost is limited.
- Prioritise GLP-1 receptor agonists for patients with diabetes at highest kidney risk.
- Use eGFR, albuminuria and the rate of eGFR decline to identify those patients.
- Consider the kidney failure risk equation when ranking competing priorities.
- Keep RAS blockade and SGLT2 inhibition as the base of kidney protection.
Why it matters
When drugs are costly, knowing who benefits most guides who should get them first.
Don't overread it
This was observational; residual confounding is possible despite the trial emulation design.
The statistics, in plain English
An overall HR of 0.84 hides big differences: almost nothing in low-risk patients, and an absolute 2.8% reduction in high-risk patients. Absolute risk reduction is the better guide to who to treat.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free